Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Fast homogeneous assay for plasma procarboxypeptidase U.

Schatteman KA, Goossens FJ, Leurs J, Kasahara Y, Scharpé SS, Hendriks DF.

Clin Chem Lab Med. 2001 Sep;39(9):806-10.

PMID:
11601677
[PubMed - indexed for MEDLINE]
2.

Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.

Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF.

Clin Chem. 1999 Jun;45(6 Pt 1):807-13.

PMID:
10351989
[PubMed - indexed for MEDLINE]
Free Article
3.

Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate.

Willemse J, Leurs J, Verkerk R, Hendriks D.

Anal Biochem. 2005 May 1;340(1):106-12.

PMID:
15802136
[PubMed - indexed for MEDLINE]
4.

Proteolytic activation of purified human procarboxypeptidase U.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Clin Chim Acta. 2000 Feb 25;292(1-2):25-40.

PMID:
10686274
[PubMed - indexed for MEDLINE]
5.

Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Thromb Haemost. 1999 Dec;82(6):1718-21.

PMID:
10613660
[PubMed - indexed for MEDLINE]
6.

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.

Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME.

Anal Biochem. 2008 Jan 1;372(1):32-40. Epub 2007 Sep 29.

PMID:
17967438
[PubMed - indexed for MEDLINE]
7.

Carboxypeptidase N: colorimetric assay using a new substrate.

Hendriks D, Scharpe S, van Sande M, Lommaert MP, Kasahara Y.

Anal Biochem. 1987 Jul;164(1):90-5.

PMID:
3118736
[PubMed - indexed for MEDLINE]
8.

Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma.

Strömqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T, Scharpé S, Hendriks D.

Thromb Haemost. 2001 Jan;85(1):12-7.

PMID:
11204563
[PubMed - indexed for MEDLINE]
9.

Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.

Antovic JP, Blombäck M.

Thromb Res. 2002 Apr 1;106(1):59-62.

PMID:
12165290
[PubMed - indexed for MEDLINE]
10.

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.

Heylen E, Van Goethem S, Willemse J, Olsson T, Augustyns K, Hendriks D.

Anal Biochem. 2010 Jan 1;396(1):152-4. doi: 10.1016/j.ab.2009.08.037. Epub 2009 Sep 2.

PMID:
19732738
[PubMed - indexed for MEDLINE]
11.

Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.

Willemse JL, Hendriks DF.

Clin Chem. 2006 Jan;52(1):30-6. Epub 2005 Nov 18. Review.

PMID:
16299049
[PubMed - indexed for MEDLINE]
Free Article
12.

A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.

Neill EK, Stewart RJ, Schneider MM, Nesheim ME.

Anal Biochem. 2004 Jul 15;330(2):332-41.

PMID:
15203340
[PubMed - indexed for MEDLINE]
13.

Colorimetric determination of carboxypeptidase A activity in serum.

Saruta H, Ashihara Y, Sugiyama M, Roth M, Miyagawa E, Kido Y, Kasahara Y.

Clin Chem. 1986 May;32(5):748-51.

PMID:
3698265
[PubMed - indexed for MEDLINE]
Free Article
14.

Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).

Bouma BN, Meijers JC.

J Thromb Haemost. 2003 Jul;1(7):1566-74. Review.

PMID:
12871292
[PubMed - indexed for MEDLINE]
15.

Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.

Valnickova Z, Thøgersen IB, Potempa J, Enghild JJ.

J Biol Chem. 2007 Feb 2;282(5):3066-76. Epub 2006 Nov 30.

PMID:
17138567
[PubMed - indexed for MEDLINE]
Free Article
16.

Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.

Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, Harrysson A, Hager AC, Wissing BM, Hendriks D, Cronet P.

FEBS J. 2006 Feb;273(4):778-92.

PMID:
16441664
[PubMed - indexed for MEDLINE]
17.

Thrombin-activatable fibrinolysis inhibitor.

Marx PF.

Curr Med Chem. 2004 Sep;11(17):2335-48. Review.

PMID:
15379716
[PubMed - indexed for MEDLINE]
18.

Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.

Antovic J, Schulman S, Eelde A, Blombäck M.

Haemophilia. 2001 Nov;7(6):557-60.

PMID:
11851753
[PubMed - indexed for MEDLINE]
19.

Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.

Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.

Hepatology. 2003 Jul;38(1):230-7.

PMID:
12830006
[PubMed - indexed for MEDLINE]
20.

Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor.

Mao SS, Colussi D, Bailey CM, Bosserman M, Burlein C, Gardell SJ, Carroll SS.

Anal Biochem. 2003 Aug 1;319(1):159-70.

PMID:
12842119
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk